We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-16.95%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.4B
AUM Growth
-$286M
Cap. Flow
-$9.42M
Cap. Flow %
-0.67%
Top 10 Hldgs %
51.45%
Holding
86
New
13
Increased
27
Reduced
13
Closed
23

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$130M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56M
3
SRRK icon
Scholar Rock
SRRK
+$50M
4
VERA icon
Vera Therapeutics
VERA
+$45.8M
5
NUVL
Nuvalent
NUVL
+$37.1M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$120M
2
MRK icon
Merck
MRK
+$79.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$52.8M
5
SLNO
Soleno Therapeutics
SLNO
+$47.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
76
Neurogene
NGNE
$712M
– –
-80,000
Closed -$1.83M
NTLA icon
77
Intellia Therapeutics
NTLA
$1.67B
– –
-525,000
Closed -$6.12M
REGN icon
78
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-20,000
Closed -$14.2M
ROIV icon
79
Roivant Sciences
ROIV
$26.2B
– –
-1,250,000
Closed -$14.8M
SLNO
80
DELISTED
Soleno Therapeutics
SLNO
– –
-1,060,000
Closed -$47.6M
SNY icon
81
Sanofi
SNY
$104B
– –
-750,000
Closed -$36.2M
TMDX icon
82
Transmedics
TMDX
$2.91B
– –
-50,000
Closed -$3.12M
VERV
83
DELISTED
Verve Therapeutics
VERV
– –
-645,000
Closed -$3.64M
ZLAB icon
84
Zai Lab
ZLAB
$2.62B
– –
-300,000
Closed -$7.86M
CMRX
85
DELISTED
Chimerix, Inc.
CMRX
– –
-1,400,000
Closed -$4.87M
ACHL
86
DELISTED
Achilles Therapeutics
ACHL
– –
-1,500,000
Closed -$1.71M
1 2 3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Vestal Point Capital held 86 positions worth $1.4B, down 17% from $1.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Vestal Point Capital's Q1 2025 filing shows 13 new, 27 increased, 13 reduced and 23 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M. The largest sale was Jazz Pharmaceuticals, an estimated $120M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Vestal Point Capital's largest Q1 2025 buy was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M.
  • Vestal Point Capital added most to Arcellx in Q1 2025, an estimated $130M increase.
  • Vestal Point Capital's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $52.8M.
  • Vestal Point Capital fully exited Jazz Pharmaceuticals in Q1 2025, selling an estimated $120M.
  • Vestal Point Capital's ten largest holdings make up 51% of its $1.4B portfolio in Q1 2025.
  • Vestal Point Capital opened 13 new positions and closed 23 in Q1 2025.
  • Vestal Point Capital's portfolio value fell 17% quarter-over-quarter to $1.4B.

Based on Vestal Point Capital's 13F filing for Q1 2025, filed 15 May 2025.